New treatments for dry eye and ocular surface diseases
Novel Treatments for Ocular Surface Diseases
This study is looking at new ways to help people with dry eye disease by using special proteins that can heal and reduce inflammation in the eye, aiming to improve comfort and vision for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10795227 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for dry eye disease (DED) and other ocular surface diseases (OSD) that significantly impact visual function and quality of life. The study investigates the use of histatin peptides, which are known for their wound healing and anti-infective properties, to reduce inflammation and improve the health of the corneal epithelium. By exploring the mechanisms of action of these peptides, the research aims to create non-toxic and anti-inflammatory treatments that can effectively address the underlying causes of these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing symptoms of dry eye disease or other ocular surface diseases.
Not a fit: Patients with ocular surface diseases caused by non-inflammatory factors or those who do not respond to peptide-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments that improve the quality of life for patients suffering from dry eye and ocular surface diseases.
How similar studies have performed: Previous research has shown promise in using peptide-based therapies for ocular conditions, indicating potential success for this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Aakalu, Vinay — University of Michigan at Ann Arbor
- Study coordinator: Aakalu, Vinay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.